Comparing two weight loss programs for children with fatty liver disease
Compares residential and outpatient weight loss programs in obese children with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Key facts
- Where
- De Haan and Ghent, BelgiumSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 18 years old?
Source: NCT05309863, who can take part
Where in Belgium
- ZeepreventoriumDe Haan, BelgiumTaking people
- AZ Jan PalfijnGhent, BelgiumTaking people
- University Hospital GentGhent, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Ghent
- Trial code
- NCT05309863
- Record updated
- 4 June 2024
- Original description
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic. Secondary to increasing rates of obesity in children and adolescents, the prevalence of NAFLD has more than doubled in the last decades and is now the most common pediatric liver disease.Read full original descriptionShow less
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic. Secondary to increasing rates of obesity in children and adolescents, the prevalence of NAFLD has more than doubled in the last decades and is now the most common pediatric liver disease.
At present, lifestyle modification by dietary intervention and increasing physical activity is the mainstay of treatment for pediatric NAFLD. Several studies have shown that lifestyle intervention and weight loss improve non-invasive markers of NAFLD. To the investigator's knowledge, data on fibrosis regression following lifestyle treatment in children and adolescents were lacking. The investigators therefore performed a prospective cohort study to investigate the impact of residential lifestyle treatment on liver steatosis and fibrosis in obese children and adolescents.
As a follow-up, the investigators now aim to compare these findings with a cohort of well-characterized patients undergoing multidisciplinary, yet ambulatory, weight loss treatment. As such, the investigators will compare the outcomes in two prospective patient cohorts in this non-randomized observational study.
Inclusion: Enrolled in the lifestyle management program for obesity in one of the participating centres.
Exclusion: Treatment with drugs which can induce liver steatosis or fibrosis (e.g. systemic corticosteroids, methotrexate); Evidence of liver disease of other causes (viral, auto-immune, genetic); Syndromic obesity; Average daily alcohol consumption of >20g/day; Unvalid screening Fibroscan.